Achtnichts L - Search Results

1

Neurofilament Light Chain Elevation and Disability Progression in Multiple Sclerosis.

Abdelhak A, Benkert P, Schaedelin S, Boscardin WJ, Cordano C, Oechtering J, Ananth K, Granziera C, Melie-Garcia L, Montes SC, Beaudry-Richard A, Achtnichts L, Oertel FC, Lalive PH, Leppert D, Müller S, Henry RG, Pot C, Matthias A, Salmen A, Oksenberg JR, Disanto G, Zecca C, D'Souza M, Du Pasquier R, Bridel C, Gobbi C, Kappos L, Hauser SL, Cree BAC, Kuhle J, Green AJ; UCSF, MS EPIC, and the SMSC Study Teams. Abdelhak A, et al. Among authors: achtnichts l. JAMA Neurol. 2023 Dec 1;80(12):1317-1325. doi: 10.1001/jamaneurol.2023.3997. JAMA Neurol. 2023. PMID: 37930670

2

Stroke-like presentation in a case of Creutzfeldt-Jakob disease.

Szabo K, Achtnichts L, Grips E, Binder J, Gerigk L, Hennerici M, Gass A. Szabo K, et al. Among authors: achtnichts l. Cerebrovasc Dis. 2004;18(3):251-3. doi: 10.1159/000080109. Epub 2004 Aug 6. Cerebrovasc Dis. 2004. PMID: 15305071 No abstract available.

3

Whole brain N-acetylaspartate concentration is conserved throughout normal aging.

Wu WE, Gass A, Glodzik L, Babb JS, Hirsch J, Sollberger M, Achtnichts L, Amann M, Monsch AU, Gonen O. Wu WE, et al. Among authors: achtnichts l. Neurobiol Aging. 2012 Oct;33(10):2440-7. doi: 10.1016/j.neurobiolaging.2011.12.008. Epub 2012 Jan 14. Neurobiol Aging. 2012. PMID: 22245316 Free PMC article.

4

Alternatives to current disease-modifying treatment in MS: what do we need and what can we expect in the future?

Kappos L, Kuhle J, Gass A, Achtnichts L, Radue EW. Kappos L, et al. Among authors: achtnichts l. J Neurol. 2004 Sep;251 Suppl 5:v57-v64. doi: 10.1007/s00415-004-1509-6. J Neurol. 2004. PMID: 15549357 Review.

5

Genomics and proteomics: role in the management of multiple sclerosis.

Kappos L, Achtnichts L, Dahlke F, Kuhle J, Naegelin Y, Sandbrink R, Lindberg RL. Kappos L, et al. Among authors: achtnichts l. J Neurol. 2005 Sep;252 Suppl 3:iii21-iii27. doi: 10.1007/s00415-005-2013-3. J Neurol. 2005. PMID: 16170496 Review.

6

Natalizumab alters transcriptional expression profiles of blood cell subpopulations of multiple sclerosis patients.

Lindberg RL, Achtnichts L, Hoffmann F, Kuhle J, Kappos L. Lindberg RL, et al. Among authors: achtnichts l. J Neuroimmunol. 2008 Feb;194(1-2):153-64. doi: 10.1016/j.jneuroim.2007.11.007. Epub 2008 Feb 21. J Neuroimmunol. 2008. PMID: 18178259

7

["Numb chin syndrome": first presenting syndrome of multiple sclerosis?].

Oestmann A, Achtnichts L, Kappos L, Gass A, Naegelin Y. Oestmann A, et al. Among authors: achtnichts l. Dtsch Med Wochenschr. 2008 Jan;133(3):76-8. doi: 10.1055/s-2008-1017477. Dtsch Med Wochenschr. 2008. PMID: 18186008 German.

8

SWiss Atorvastatin and interferon Beta-1b trial In Multiple Sclerosis (SWABIMS)--rationale, design and methodology.

Kamm CP, Mattle HP; SWABIMS Study Group. Kamm CP, et al. Trials. 2009 Dec 14;10:115. doi: 10.1186/1745-6215-10-115. Trials. 2009. PMID: 20003436 Free PMC article. Clinical Trial.

9

Global N-acetylaspartate concentration in benign and non-benign multiple sclerosis patients of long disease duration.

Achtnichts L, Gonen O, Rigotti DJ, Babb JS, Naegelin Y, Penner IK, Bendfeldt K, Hirsch J, Amann M, Kappos L, Gass A. Achtnichts L, et al. Eur J Radiol. 2013 Dec;82(12):e848-52. doi: 10.1016/j.ejrad.2013.08.037. Epub 2013 Sep 4. Eur J Radiol. 2013. PMID: 24041438 Free PMC article.

10

Cryptococcal Meningoencephalitis in a Patient With Multiple Sclerosis Treated With Fingolimod.

Achtnichts L, Obreja O, Conen A, Fux CA, Nedeltchev K. Achtnichts L, et al. JAMA Neurol. 2015 Oct;72(10):1203-5. doi: 10.1001/jamaneurol.2015.1746. JAMA Neurol. 2015. PMID: 26457631 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

39 results

Search Page